Original Publication Date: 1 August, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Johanna Mondesir, Pierre Sujobert, Mark A Murakami et al
Until recently, the treatment of blood cancers has rested exclusively on chemotherapy, radiation and, in select cases, stem cell transplantation, giving rise to frequent and sometimes life-threatening side effects. The past 10 years have witnessed dramatic clinical advances due to the development of novel therapies, hereafter referred to as targeted therapies, which specifically inhibit molecules that are essential to the pathophysiology of individual malignancies.